MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company focused on improving patient safety and clinical outcomes, today announced an upcoming Continuing Education webinar to be presented by internationally recognized vascular access expert Dr. Nancy Moureau and hosted by the distinguished Association for Vascular Access (AVA), a leading global authority on vascular access. The webinar will. ...

Core Insights - Philips reported strong fourth-quarter results with a 7% growth in order intake and comparable sales, reflecting consistent delivery against commitments and improving order momentum [5][6] - The company achieved EUR 248 million in productivity savings in Q4, bringing total productivity savings to EUR 850 million for 2025, exceeding the original outlook [1][6] - For 2026, Philips anticipates comparable sales growth of 3% to 4.5% and an adjusted EBITDA margin of 12.5% to 13% [17] Financial Performance - In Q4, Philips generated EUR 1.2 billion in free cash flow, although this was EUR 85 million lower year over year due to a prior year's insurance receipt [8] - The company ended the quarter with approximately EUR 2.8 billion in cash and net debt of approximately EUR 5.3 billion, with a leverage ratio of 1.7x net debt to adjusted EBITDA [9] - Full-year free cash flow was EUR 512 million, ahead of outlook, following significant cash payments related to U.S. medical monitoring settlements [8] Sales and Order Intake - Order intake grew 6% for the full year, with equipment order intake rising 7% in Q4, driven by strong performance in North America [2][5] - For 2025, comparable sales growth was reported at 2.3%, with an adjusted EBITDA margin increase of 80 basis points to 12.3% [3] Segment Performance - Connected Care saw a 7% growth in comparable sales in Q4, supported by strong demand in monitoring and enterprise informatics [3] - The D&T segment reported a 5% increase in order intake for the year, with strong demand for Image-Guided Therapy and Precision Diagnosis [11] Strategic Initiatives - Philips announced an additional EUR 1.5 billion productivity program for 2026-2028, aimed at further enhancing operational efficiency [19] - The company emphasized innovation as a key driver of growth, highlighting new product launches such as a helium-free MRI and an AI-enabled navigation solution [10] Regional Insights - North America showed strong market fundamentals with increasing demand for secure, productivity-enhancing platforms, while China presented challenges due to longer processing times and tougher competition [14][15] - In Personal Health, demand remained resilient in the U.S., but consumer sentiment in China was cautious, leading to a reduction in trade inventory [16] Tariff Impact - Incremental tariff headwinds were slightly better than expected, with mitigation actions in place to fully address these challenges by 2028 [7] - For 2026, tariff costs are expected to have a net impact of EUR 250 million to EUR 300 million, with a slight decline in margin anticipated in Q1 due to these headwinds [18]

Core Insights - Stryker has announced the limited market release of Mako RPS (Robotic Power System) for Total Knee, expanding its Mako robotics platform into a new segment [1][2] - Mako RPS is compatible with Stryker's Triathlon Total Knee System and aims to provide surgeons with the benefits of robotic technology while maintaining the familiarity of manual power tools [2][3] Company Overview - Stryker is a global leader in medical technologies, impacting over 150 million patients annually through innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [5] - The company emphasizes its commitment to advancing orthopaedic patient outcomes through robotics, with nearly 20 years of experience and over 2 million procedures performed globally [3] Product Features - Mako RPS for Total Knee includes intraoperative planning and a robotically enabled saw that utilizes Stryker's patented active adjustment technology, aligning with the surgical plan based on the surgeon's hand movements [3] - The system integrates seamlessly into a surgeon's workflow, providing a familiar cutting experience without the need for cutting blocks, and is designed to work with Stryker's Q Guidance System [3]

Group 1 - The article emphasizes the growing interest in small-cap value stocks as the market broadens beyond mega-cap tech stocks, which have dominated investment flows in recent years [2][21] - In Q4, the Russell 2000® Value Index returned 3.26%, outperforming the S&P 500's 2.66% gains, indicating a significant relative performance improvement for small stocks [3] - Small companies are projected to experience profit growth that will surpass large caps for the first time in 13 quarters, supported by favorable economic conditions such as lower interest rates and improved regulatory environments [4] Group 2 - Valuations of small stocks are becoming more attractive, with recent private acquisitions indicating increased investor interest; four holdings were taken private in the last quarter, raising the total to 14 for the year [5] - Despite the concentration of market capitalization, where just 10% of companies account for over 75% of the market, there is a belief that the small-cap rebound is still in its early stages [6] - The Heartland Value Fund gained 2.61% in Q4, slightly underperforming the Russell 2000® Value Index, but has outpaced it over longer time frames [9] Group 3 - Integer Holdings Corporation faced a significant stock decline of over 30% after lowering its growth outlook, but management remains optimistic about future growth and margin expansion [11] - Columbus McKinnon Corporation's stock dropped more than 40% following a $2.7 billion acquisition announcement, despite management's plans to improve growth and margin profiles post-acquisition [13][14] - Alexander & Baldwin's stock was down over 14% due to concerns about tourism, but the company was taken private at a 40% premium, indicating renewed investor interest in undervalued companies [20]

Company Overview - Alphatec Holdings, Inc. is a U.S.-based medical technology company that specializes in innovative solutions for spinal surgery, focusing on proprietary platforms and expanding its portfolio to address complex spinal conditions [6]. Insider Trading Activity - Craig E. Hunsaker, EVP of People & Culture at Alphatec Holdings, executed an open-market sale of 32,584 shares valued at $679,050.56 on December 10, 2025, at a price of $20.84 per share [4][5]. - This sale represented 2.53% of Hunsaker's direct ownership at the time, which is slightly below his historical median of 2.79% for sell trades [3]. - The transaction size was significantly below Hunsaker's recent median sale of 60,876 shares, indicating a smaller-than-usual transaction [4][5]. Market Performance - Alphatec's stock has seen a remarkable 116% rise over the last year, outperforming the S&P 500's 15% total return and the 2.8% decline in the State Street SPDR Health Care Equipment ETF [8]. - Despite a solid preliminary report in January 2026, the stock experienced a nearly 22% drop in one day due to a disappointing mid-teens growth projection, and the company remains unprofitable [9]. Strategic Developments - Alphatec recently announced a partnership with Theradaptive, granting it exclusive U.S. rights to commercialize the OsteoAdapt spinal fusion technology, which is still in clinical trials. This partnership could lead to surgeon adoption and revenue growth if successful [9].

Group 1 - Johnson & Johnson is planning to spin off its orthopaedics business, DePuy Synthes, which is expected to raise its price-to-earnings multiple due to slower growth compared to its core pharmaceutical franchise [1] - The company previously spun off Kenvue, its over-the-counter drug business, which also positively impacted its valuation [1] - The stock experienced a decline of more than $5 in a single day, presenting a potential entry point for investors [1] Group 2 - Johnson & Johnson develops and sells a range of healthcare products, including pharmaceuticals and medical technologies, with a focus on various therapeutic areas such as immunology, oncology, and cardiovascular care [2] - The company is recognized for its strong franchises, and there is a particular interest in its current strategy of spinning off its commoditized artificial joint business [2]

Core Viewpoint - Stryker is set to report its financial results for the fourth quarter and full year of 2025 on January 29, 2026, with a press release and webcast scheduled for that day [1][2]. Financial Reporting - The financial results will be announced in a press release at approximately 4:05 p.m. ET on January 29, 2026, which will include summary financial information for the fourth quarter and full year ending December 31, 2025 [1]. - A webcast to discuss these results will take place at 4:30 p.m. ET on the same day, with an archive available on the company's website two hours after the live call [2]. Company Overview - Stryker is recognized as a global leader in medical technologies, focusing on improving healthcare through innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [3]. - The company impacts over 150 million patients annually, emphasizing its commitment to enhancing patient and healthcare outcomes [3].

Core Viewpoint - Stryker has announced a quarterly dividend increase to $0.88 per share, reflecting a 4.8% rise compared to the previous year and quarter [1][2]. Company Overview - Stryker is a global leader in medical technologies, focusing on improving healthcare through innovative products and services in MedSurg, Neurotechnology, and Orthopaedics, impacting over 150 million patients annually [3].

Core Viewpoint - Teleflex Incorporated has announced the sale of its Acute Care, Interventional Urology, and OEM businesses for a total of $2.03 billion in cash, which will enhance its focus on core medical technology markets and allow for significant capital return to shareholders through a new $1 billion share repurchase program [1][2][4][6]. Group 1: Transaction Details - The transactions involve the sale of the OEM business for approximately $1.5 billion and the Acute Care and Interventional Urology businesses for $530 million, with net proceeds expected to be around $1.8 billion after tax [4]. - The completion of these transactions is anticipated in the second half of 2026, pending regulatory approvals and other customary closing conditions [3]. Group 2: Strategic Focus - The company aims to optimize its portfolio and position itself as a leader in critical care and high acuity hospital markets, focusing on Vascular Access, Interventional, and Surgical businesses [2]. - Following the transactions, Teleflex expects to achieve mid-single-digit growth and enhance operational efficiency, which will drive value for shareholders and improve service delivery to customers and patients [2]. Group 3: Share Repurchase Program - The Board of Directors has authorized a share repurchase program of up to $1 billion, primarily funded by the proceeds from the recent sales [6]. - The repurchase strategy will be flexible, depending on market conditions and other factors, and may include various methods such as open market transactions and privately negotiated deals [7]. Group 4: Advisory Support - Centerview Partners LLC is acting as the financial advisor, while Simpson Thacher & Bartlett LLP serves as legal counsel, and Joele Frank provides strategic communications support to Teleflex [8].

Market Overview - U.S. stock futures showed mixed results, with Dow futures decreasing approximately 0.1% on Monday [1] Company-Specific Movements - Meihua International Medical Technologies Co., Ltd. (NASDAQ:MHUA) announced its delisting from Nasdaq, leading to a significant pre-market decline of 32.9%, bringing shares down to $9.41 [1] - SMX (Security Matters) Public Limited Company (NASDAQ:SMX) shares fell 17.2% to $275.00 after a substantial increase of 135% on the previous Friday [3] - Gulf Resources, Inc. (NASDAQ:GURE) saw a decline of 16.1% to $6.87 following a 4% drop on Friday [3] - Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) shares decreased by 16.1% to $5.35 after a notable surge of 98% on Friday [3] - Fly-E Group, Inc. (NASDAQ:FLYE) experienced a 14.4% drop to $7.08 after receiving a delinquency notice from Nasdaq regarding a delayed Form 10-Q [3] - Ecarx Holdings Inc. (NASDAQ:ECX) shares fell 9.1% to $1.91 after an 8% gain on Friday [3] - Arteris Inc (NASDAQ:AIP) saw a decline of 7.1% to $16.30 in pre-market trading [3] - Veracyte Inc (NASDAQ:VCYT) shares decreased by 5.7% to $42.06 after a 6% decline on Friday [3] - Chagee Holdings Ltd (NASDAQ:CHA) shares fell 4.6% to $13.91 in pre-market trading [3] - PureTech Health PLC (NASDAQ:PRTC) experienced a 4.2% decline to $17.30, despite announcing a successful end-of-Phase 2 meeting with the FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis [3] - PepGen Inc (NASDAQ:PEPG) shares declined by 3.9% to $5.23 in pre-market trading [3]